淋巴细胞参与肺动脉高血压的病理
Michał Tomaszewski1, Agnieszka Styczeń1, Martyna Krysa1
1Department of Cardiology, Medical University of Lublin, Jaczewskiego 8 Street, 20-954 Lublin, Poland.
调节性T细胞 (Tregs) 和免疫检查点PD-1/PD-L1与肺动脉高血压 (PAH) 有关. 这项研究发现PAH患者的Tregs和PD-1/PD-L1表达增加,这表明了新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 心血管医学 心血管医学
- 肺部病理学 肺部病理学
背景情况:
- 肺动脉高血压 (PAH) 涉及免疫失调.
- 调节性T细胞 (Tregs) 和免疫检查点 (PD-1/PD-L1) 是PAH病变的潜在因素.
研究的目的:
- 研究Tregs和免疫检查点分子PD-1和PD-L1在PAH患者中的作用.
- 分析不同类型的PAH的外周血液淋巴细胞亚群.
主要方法:
- 从25名PAH患者和对照组的外周血液单核细胞的流细胞计分析.
- 对Treg细胞百分比的量化.
- 对T细胞和B细胞的PD-1和PD-L1表达的评估.
主要成果:
- 与对照组和其他PAH亚型相比,在异形性PAH (iPAH) 患者中观察到显著更高的Treg百分比.
- 在所有PAH组中的CD4+和CD8+淋巴细胞上检测到PD-1和PD-L1的过度表达,特别是在iPAH和CHD-PAH中.
- 这些发现支持Treg功能障碍和PD-1/PD-L1在PAH中的参与.
结论:
- 免疫检查点向和Treg调节可能为PAH提供新的治疗策略.
- 需要进一步的研究来验证生物标志物并探索PAH诊断和管理中的临床实用性.
更多相关视频
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
